Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any primary ovarian failure in which the cause of the disease is a mutation in the FIGLA gene.
Features include always present findings: Female infertility; and common findings: Hypoplasia of the uterus and Streak ovary. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 3 | Secondary amenorrhea, Female infertility, Primary amenorrhea |
FIGLA encodes folliculogenesis specific bHLH transcription factor (219 aa). Germline specific transcription factor implicated in postnatal oocyte-specific gene expression. Highest expression in Testis (0.8 TPM) and Uterus (0.8 TPM).
Premature ovarian failure 6 is associated with mutations in the FIGLA gene on chromosome 2.
FIGLA is classified as a druggable target (Transcription Factor and Transcription Factor Complex categories) with score 0.0.
Genetic testing for FIGLA is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for premature ovarian failure 6 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 2 common features.
No clinical trials have been registered for premature ovarian failure 6.
148 publications have been identified in PubMed for premature ovarian failure 6. Research spans Epidemiology / Natural History (39%), Basic Science / Preclinical (25%), and Review / Meta-Analysis (20%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 57 | 39% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:37 PM UTC
Online Mendelian Inheritance in Man
2 |
Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level |
Laboratory research
37 |
25% |
Research summaries | 30 | 20% |
Clinical study results | 9 | 6% |
Patient case studies | 7 | 5% |
Other research | 3 | 2% |
Testing and diagnosis research | 3 | 2% |
New treatment approaches | 2 | 1% |
Gootzen TA (2026). [PMID: 41955317](https://pubmed.ncbi.nlm.nih.gov/41955317/). *J Natl Cancer Inst*. [Epidemiology / Natural History]
Grandi G (2026). [PMID: 42132994](https://pubmed.ncbi.nlm.nih.gov/42132994/). *Fam Cancer*. [Epidemiology / Natural History]
Miyamoto W (2026). [PMID: 40010745](https://pubmed.ncbi.nlm.nih.gov/40010745/). *Tohoku J Exp Med*. [Case Report / Case Series]
Gong LY (2026). [PMID: 41814824](https://pubmed.ncbi.nlm.nih.gov/41814824/). *Zhongguo Zhong Yao Za Zhi*. [Basic Science / Preclinical]
Akgün M (2026). [PMID: 42056651](https://pubmed.ncbi.nlm.nih.gov/42056651/). *Reprod Sci*. [Basic Science / Preclinical]
Chen JH (2026). [PMID: 41640848](https://pubmed.ncbi.nlm.nih.gov/41640848/). *Front Public Health*. [Epidemiology / Natural History]
Zhou S (2026). [PMID: 41933758](https://pubmed.ncbi.nlm.nih.gov/41933758/). *Int J Biol Macromol*. [Basic Science / Preclinical]
Wang Z (2026). [PMID: 41241170](https://pubmed.ncbi.nlm.nih.gov/41241170/). *Chem Biol Interact*. [Basic Science / Preclinical]
Mafra A (2026). [PMID: 41572237](https://pubmed.ncbi.nlm.nih.gov/41572237/). *BMC Womens Health*. [Basic Science / Preclinical]
Roth-Hochreutener M (2026). [PMID: 41681897](https://pubmed.ncbi.nlm.nih.gov/41681897/). *Cancers (Basel)*. [Review / Meta-Analysis]